SRRA News and Press, Sierra Oncology Inc.

Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...

Zendesk to be acquired by an investor group led by investment firms Permira and Hellman & Friedman in an all-cash transaction valued at approximately $10.2 billion. The price that Zendesk finally settled for was 40% below the midpoint of the original offer made by the same group o...

– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The market is beginning to turn the corner after a very uninspiring performance in most of the first half. Logic dictates that the rebound will likely be led by beaten-down sectors and stocks. On that count, pharma and biot...

The Federal Trade Commission later in June will hold a two-day workshop to "explore new approaches to enforcing the antitrust laws in the pharmaceutical industry." Speakers at the meeting, which will run June 14 and 15, include FTC Commissioner Rebecca Kelly Slaughter. In March 2021, Slaughte...

– MOMENTUM data demonstrate potential use of momelotinib in myelofibrosis patients who are symptomatic and anemic – – Additional data highlight improved transfusion independence, symptoms and spleen volume of cytopenic myelofibrosis patients – ...

Form 13F filings show fund managers' top merger arbitrage stocks. Top M&A stocks of the 31 funds I follow. Cerner the top merger arb stock. For further details see: Top Merger Stocks Held By Fund Managers, Mid-Q2 2022

– Oral presentation of MOMENTUM pivotal phase 3 data in myelofibrosis patients who are symptomatic and anemic – – Poster presentation to highlight improved transfusion independence, symptoms and spleen volume of these myelofibrosis patients who also presen...

Sierra Oncology press release (NASDAQ:SRRA): Q1 GAAP EPS of -$1.33 misses by $0.30. Cash and cash equivalents totaled $274M as of March 31, 2022. “By entering into a merger agreement with GSK, we are one step closer to realizing our mission of delivering transformative therapies for pa...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended March 31, 2022. “By entering into a merg...